Genetic aberrations and survival in plasma cell leukemia

被引：211

作者：

Tiedemann, R. E. ^{[1
]}

Gonzalez-Paz, N. ^{[2
]}

Kyle, R. A. ^{[2
]}

Santana-Davila, R. ^{[3
]}

Price-Troska, T. ^{[2
]}

Van Wier, S. A. ^{[1
]}

Chng, W. J. ^{[1
]}

Ketterling, R. P. ^{[4
]}

Gertz, M. A. ^{[2
]}

Henderson, K. ^{[2
]}

Greipp, P. R. ^{[2
]}

Dispenzieri, A. ^{[2
]}

Lacy, M. Q. ^{[2
]}

Rajkumar, S. V. ^{[2
]}

Bergsagel, P. L. ^{[1
]}

Stewart, A. K. ^{[1
]}

Fonseca, R. ^{[1
]}

机构：

[1] Mayo Clin, Arizona Canc Ctr, Div Hematol Oncol, Scottsdale, AZ 85259 USA

[2] Mayo Clin, Div Hematol, Rochester, MN USA

[3] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA

[4] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA

来源：

LEUKEMIA | 2008年 / 22卷 / 05期

关键词：

translocation; deletion; p53; cyclin D; RAS; MYC;

D O I：

10.1038/leu.2008.4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that originates either as primary disease (pPCL) or as a secondary leukemic transformation (sPCL) of multiple myeloma (MM). We report here the genetic aberrations and survival of 80 patients with pPCL or sPCL and make comparisons with 439 cases of MM. pPCL presents a decade earlier than sPCL (54.7 vs 65.3 years) and is associated with longer median overall survival (11.1 vs 1.3 months; P < 0.001). 14q32 (IgH) translocations are highly prevalent in both sPCL and pPCL (82-87%); in pPCL IgH translocations almost exclusively involve 11q13 (CCND1), supporting a central etiological role, while in sPCL multiple partner oncogenes are involved, including 11q13, 4p16 (FGFR3/MMSET) and 16q23 (MAF), recapitulating MM. Both show ubiquitous inactivation of TP53 (pPCL 56%; sPCL 83%) by coding mutation or 17p13 deletion; complemented by p14ARF epigenetic silencing in sPCL (29%). Both show frequent N-RAS or K-RAS mutation. Poor survival in pPCL was predicted by MYC translocation (P = 0.006). Survival in sPCL was consistently short. Overall pPCL and sPCL are different disorders with distinct natural histories, genetics and survival.

引用

页码：1044 / 1052

页数：9

共 47 条

[31]

Jaffe E.S., 2001, PATHOLOGY GENETICS T, V3

[32] Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis [J].

Kato, S ;

Han, SY ;

Liu, W ;

Otsuka, K ;

Shibata, H ;

Kanamaru, R ;

Ishioka, C .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) :8424-8429

[33]

KYLE RA, 1990, ACTA ONCOL, V29, P1

[34] PLASMA-CELL LEUKEMIA - REPORT ON 17 CASES [J].

KYLE, RA ;

MALDONADO, JE ;

BAYRD, ED .

ARCHIVES OF INTERNAL MEDICINE, 1974, 133 (05) :813-817

[35] Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions [J].

Leslie, NR ;

Bennett, D ;

Gray, A ;

Pass, I ;

Hoang-Xuan, K ;

Downes, CP .

BIOCHEMICAL JOURNAL, 2001, 357 :427-435

[36] K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements [J].

Liang, DC ;

Shih, LY ;

Fu, JF ;

Li, HY ;

Wang, HI ;

Hung, IJ ;

Yang, CP ;

Jaing, TH ;

Chen, SH ;

Liu, HC .

CANCER, 2006, 106 (04) :950-956

[37] Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia [J].

Magdinier, F ;

Wolffe, AP .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (09) :4990-4995

[38] Twenty years of p53 research: structural and functional aspects of the p53 protein [J].

May, P ;

May, E .

ONCOGENE, 1999, 18 (53) :7621-7636

[39] PLASMA-CELL LEUKEMIA - AN EVALUATION OF RESPONSE TO THERAPY [J].

NOEL, P ;

KYLE, RA .

AMERICAN JOURNAL OF MEDICINE, 1987, 83 (06) :1062-1068

[40]

Oken MM, 1999, CANCER, V86, P957

← 1 2 3 4 5 →